Brokerages Set PepGen, Inc. (NASDAQ:PEPG) PT at $12.00

Shares of PepGen, Inc. (NASDAQ:PEPG) have been assigned a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $12.00.

A number of equities analysts recently weighed in on the company. Wall Street Zen raised PepGen from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Guggenheim lifted their target price on shares of PepGen from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. HC Wainwright upped their price target on shares of PepGen from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of PepGen in a research note on Thursday, January 22nd.

PepGen Stock Down 0.3%

PEPG opened at $6.32 on Friday. The firm has a market cap of $434.50 million, a PE ratio of -2.24 and a beta of 1.91. The business has a fifty day simple moving average of $5.80 and a 200-day simple moving average of $4.50. PepGen has a fifty-two week low of $0.88 and a fifty-two week high of $7.80.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Rangeley Capital LLC increased its holdings in PepGen by 133.3% in the second quarter. Rangeley Capital LLC now owns 35,000 shares of the company’s stock worth $39,000 after buying an additional 20,000 shares during the last quarter. Marshall Wace LLP bought a new stake in PepGen in the second quarter worth approximately $44,000. Heights Capital Management Inc. acquired a new position in shares of PepGen during the 3rd quarter worth $46,000. Burkehill Global Management LP bought a new position in shares of PepGen during the 3rd quarter valued at $46,000. Finally, Militia Capital Partners LP bought a new position in shares of PepGen during the 3rd quarter valued at $72,000. Hedge funds and other institutional investors own 58.01% of the company’s stock.

PepGen Company Profile

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).